DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology
Montrouge, France, July 7, 2020
DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology
PEOPLE is the largest long-term peanut allergy immunotherapy trial to date and showed favorable benefit-to-risk across three-year treatment period with Viaskin Peanut
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that The Journal of Allergy and Clinical Immunology (JACI) has published results from its three-year, open-label extension of the Phase III PEPITES study (PEOPLE). The study was published online today and will be in an upcoming print edition of the journal.
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment with Viaskin Peanut (compound name DBV712 250 μg), with low discontinuations due to adverse events. Top-line data from PEOPLE were announced in January 2020 and presented with additional detail at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2020 Annual Meeting in March. The Biologics License Application (BLA) for investigational DBV712 for peanut-allergic children ages 4-11 years is currently under review by the U.S. Food and Drug Administration (FDA). If approved, DBV712 would be the first once-daily, non-invasive epicutaneous treatment option for children living with peanut allergy.
“These data from the largest long-term study of peanut allergy immunotherapy demonstrate continued treatment benefit of DBV712 beyond one year, as well as a decrease in adverse events,” said David Fleischer, M.D., Principal Investigator of PEPITES and PEOPLE, Professor of Pediatrics and Section Head, Children’s Hospital Colorado. “In my clinical practice, I see many patients and their families who struggle with the burden of peanut allergy and the fear of accidental exposure. The potential benefit of an easy to use, well-tolerated treatment with long-term effect would be a welcome option for these patients.”
PEOPLE Efficacy Results
Data from the PEOPLE trial demonstrate that DBV712 was associated with continued response over a three-year treatment period.
- 75.9% (107/141) saw an improvement in eliciting dose (ED) from baseline to Month 36.
- 51.8% (73/141) achieved an ED of at least 1,000 mg at Month 36.
- At Month 36, the mean cumulative reactive dose (CRD) was 1,768.8 mg (median 944 mg) compared to 223.8 mg (median 144 mg) at baseline.
- A treatment effect was seen across the spectrum of baseline sensitivity, including the most sensitive patients; those who entered with an ED of less than or equal to 10 mg (n=18) saw a 22.5-fold increase in geometric mean ED over the treatment period.
- Consistent with the high rate of sustained unresponsiveness reported in a previous clinical study1, exploratory analyses in a subset of participants showed that 77.8% (14/18) were able to maintain desensitization, according to predefined study definition, for a two-month period while off therapy and without peanut consumption.
Lesen Sie auch
PEOPLE Safety and Tolerability Results